CoChat

Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.

Takechi, T, Fujioka, A, Matsushima, E, Fukushima, M · 2002 · European Journal of Cancer

The DOI matches its Crossref record; 31 of the 40 references it cites were found in a registry or an index.

Abstract

The purpose of this study was to evaluate the use of 5-chloro-2,4-dihydroxypyridine (CDHP), a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), to enhance the antitumour activity of the fluoropyrimidines. In an in vitro study, CDHP did not influence cell proliferation by itself. However, CDHP did inhibit 5-fluorouracil (5-FU) degradation and enhanced 5-FU cytotoxicity in a concentration-dependent manner in two human tumour cell lines (MIAPaCa-2 and HuTu80) with relatively high basal DPD activity. CDHP exhibited a maximum effect at a molar ratio (CDHP:5-FU) of more than 0.2. However, CDHP did not have any effect on 5-FU cytotoxicity in the CAL27 tumour cell line, which has a relatively low basal DPD activity, even at concentrations where the DPD activity is almost completely inhibited. In an in vivo study, the maximal tolerable doses (MTD) of tegafur (FT) and a combination of FT and CDHP at a molar ratio of 1:0.4 (FT/CDHP) for nude mice were determined by oral administration for 14 consecutive days. After a single oral administration of either FT or FT/CDHP at the MTD, the 5-FU serum concentration-time profiles were almost the same for both treatment strategies. When nude mice bearing subcutaneous (s.c.) MIAPaCa-2 cells were treated with either FT or FT/CDHP at the MTD, the FT/CDHP treatment showed a significantly higher antitumour effect than the FT treatment (tumour growth inhibition: FT/CDHP, 51+/-12%; FT, 21+/-25%; P<0.05). However, the host-body weight suppression induced by FT/CDHP and FT was equivalent. These findings suggest that the combination of fluoropyrimidine and CDHP for the treatment of tumours with a high basal DPD elicits a greater antitumour effect than treatment with fluoropyrimidines alone and we suggest that CDHP inhibits the degradation of 5-FU in the tumour.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0959-8049(02)00048-5

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Research works printed but not linked: 5

  1. Hoff, 1999, Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, Semin. Oncol., 26, 52
  2. Carmichael, 1987, Evaluation of a tetrazolium-based semiautomated colorimetric assay, Cancer Res., 47, 936
  3. Cao, 1995, 5-Ethynyluracil (776C85), Cancer Res., 55, 6227
  4. Cao, 1994, 5-Ethynyluracil (776C85), Cancer Res., 54, 1507
  5. Nagayama, 1997, Disposition of components of new anti-cancer drug S-1 (7), Xenobio Metabol. Dispos., 12, 645

Cited by

See all 87

Metadata

Authors
Takechi, T., Fujioka, A., Matsushima, E., & Fukushima, M.
Affiliations
Taiho Pharmaceutical (Japan) (JP)
Corresponding author
Takechi, T
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2002-06
Volume
38
Issue
9
Pages
1271-1277
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2097303718
Cited by
85
References
40
Citations by year
2023: 1 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 4 · 2013: 7 · 2012: 5
FWCI
1.39
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • European Journal of Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
5-fluorouracil, dihydropyrimidine dehydrogenase, tegafur, antitumour activity, combination chemotherapy, cancer cell lines, MIA PaCa-2 cells
MeSH terms
Animals, Drug Interactions, Fluorouracil, Maximum Allowable Concentration, Mice, Inbred BALB C, Neoplasm Transplantation, Oxidoreductases, Pancreatic Neoplasms, Pyridines, Tumor Cells, Cultured, Dihydrouracil Dehydrogenase (NADP), Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. https://app.cochat.ai/papers/10.1016/s0959-8049(02)00048-5
The paper
Takechi, T., Fujioka, A., Matsushima, E., & Fukushima, M. (2002). Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. European Journal of Cancer. https://doi.org/10.1016/s0959-8049(02)00048-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.